Spero Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing a strategic shift toward SP001 development following the FDA's June 2026 approval of Utebzi.

Key Highlights

  • FDA Approval: The FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil) in June 2026, according to the filing.
  • Strategic Shift: Following the Utebzi approval, the company disclosed it "shifted our focus and resources to advancing the development of SP001."
  • Key Dependency: The filing states that the company's "business and prospects are substantially dependent on the successful development of SP001."
  • Shares Outstanding: As of November 6, 2026, the registrant had 58,264,577 shares of common stock outstanding at $0.001 par value per share.
  • Utebzi Royalties: The company disclosed it receives royalties on Utebzi sales, with amounts paid to affiliates of Healthcare Royalty Management, LLC under milestone and royalty financing transaction agreements.
  • Filer Status: Spero Therapeutics is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.

Spero Therapeutics Pivots to SP001 After Utebzi Receives FDA Clearance

Spero Therapeutics, Inc. (NASDAQ:SPRO), headquartered in Cambridge, Massachusetts, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing describes a significant strategic reorientation: following the FDA's June 2026 approval of GSK's NDA resubmission for Utebzi (tebipenem pivoxil), the company stated it has redirected its focus and resources toward developing SP001, an early-stage product candidate. The filing notes that the company anticipates filing a U.S. Investigational New Drug application for SP001.

According to the filing, the company's ability to realize value from Utebzi now depends on commercialization efforts conducted through its partnership with GlaxoSmithKline Intellectual Property (No. 3) Limited under the GSK License Agreement. The company disclosed that it may receive milestone payments and royalties on future Utebzi sales under that agreement, while also noting royalty obligations owed to affiliates of Healthcare Royalty Management, LLC under separate financing transaction agreements.

The filing identifies several risk factors specific to this period. It cautions that failure to execute successfully on SP001 development "may be materially adversely affected" for the company's business and prospects. The filing also notes that preliminary or interim clinical data may change as more patient data become available, and that serious adverse events identified during development or after approval could delay or prevent regulatory approvals. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding. The filing contains forward-looking statements subject to the company's cautionary language and the risk factors described within it.

What Was Disclosed

Spero Therapeutics filed a quarterly report covering the period ended September 30, 2026, disclosing the FDA's June 2026 Utebzi approval, a resulting strategic shift to SP001 development, royalty arrangements with GSK and Healthcare Royalty Management affiliates, and 58,264,577 shares outstanding as of November 6, 2026.